276 related articles for article (PubMed ID: 36096781)
1. Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
Tu Z; Ji Q; Han Q; Long X; Li J; Wu L; Huang K; Zhu X
BMC Cancer; 2022 Sep; 22(1):973. PubMed ID: 36096781
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional Patterns of Lower-Grade Glioma Patients with Distinct Ferroptosis Levels, Immunotherapy Response, and Temozolomide Sensitivity.
Tu Z; Li J; Long X; Wu L; Zhu X; Huang K
Oxid Med Cell Longev; 2022; 2022():9408886. PubMed ID: 35592529
[TBL] [Abstract][Full Text] [Related]
3. Construction of a novel molecular typing and scoring system for anoikis distinguishes between different prognostic risks and treatment responsiveness in low-grade glioma.
Zhang G; Chen A; Fang J; Wu A; Chen G; Tai P; Chen H; Chen X; Cao K
Front Immunol; 2023; 14():1105210. PubMed ID: 37114037
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
Jiang H; Sun Z; Li F; Chen Q
Front Immunol; 2022; 13():983569. PubMed ID: 36405708
[TBL] [Abstract][Full Text] [Related]
5. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
6. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
8. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
[TBL] [Abstract][Full Text] [Related]
11. Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas.
Zhou Z; Wei J; Jiang W
Sci Rep; 2022 Mar; 12(1):5457. PubMed ID: 35361903
[TBL] [Abstract][Full Text] [Related]
12. N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma.
Maimaiti A; Feng Z; Liu Y; Turhon M; Xie Z; Baihetiyaer Y; Wang X; Kasimu M; Jiang L; Wang Y; Wang Z; Pei Y
Eur J Med Res; 2023 Mar; 28(1):144. PubMed ID: 36998056
[TBL] [Abstract][Full Text] [Related]
13. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
[TBL] [Abstract][Full Text] [Related]
14. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.
Gao Y; Weenink B; van den Bent MJ; Erdem-Eraslan L; Kros JM; Sillevis Smitt P; Hoang-Xuan K; Brandes AA; Vos M; Dhermain F; Enting R; Ryan GF; Chinot O; Ben Hassel M; van Linde ME; Mason WP; Gijtenbeek JMM; Balana C; von Deimling A; Gorlia T; Stupp R; Hegi ME; Baumert BG; French PJ
Eur J Cancer; 2018 May; 94():168-178. PubMed ID: 29571083
[TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy.
Cheng Q; Duan W; He S; Li C; Cao H; Liu K; Ye W; Yuan B; Xia Z
Front Cell Dev Biol; 2021; 9():686909. PubMed ID: 34336837
[TBL] [Abstract][Full Text] [Related]
16. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas.
Zhang G; Tai P; Fang J; Chen A; Chen X; Cao K
Front Oncol; 2023; 13():1157115. PubMed ID: 37051542
[TBL] [Abstract][Full Text] [Related]
18. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
19. Elucidating the Role of Pyroptosis in Lower-Grade Glioma: Development of a Novel Scoring System to Enhance Personalized Therapeutic Approaches.
Chen X; Xu Y; Wang M; Ren C
J Mol Neurosci; 2023 Aug; 73(7-8):649-663. PubMed ID: 37566191
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
